Neurology

Rose Hill Announces Addition of Two Senior Advisors to Advisory TeamRose Hill Announces Addition of Two Senior Advisors to Advisory Team

Rose Hill Announces Addition of Two Senior Advisors to Advisory Team

Burton J. Tabaac MD, FAHA and Rotem Petranker, M.A. Set to Bolster Rose Hill’s Psychedelic Research EffortsWORCESTER, Mass., Aug. 21,…

8 months ago
Real-world Evidence Solutions Market to be Worth $6.37 Billion by 2031–Exclusive Report by Meticulous Research®Real-world Evidence Solutions Market to be Worth $6.37 Billion by 2031–Exclusive Report by Meticulous Research®

Real-world Evidence Solutions Market to be Worth $6.37 Billion by 2031–Exclusive Report by Meticulous Research®

REDDING, Calif., Aug. 19, 2024 /PRNewswire/ -- According to a new market research report titled, "Real-world Evidence Solutions Market Size, Share, Forecast,…

8 months ago
Ardent Health Reports Second Quarter 2024 ResultsArdent Health Reports Second Quarter 2024 Results

Ardent Health Reports Second Quarter 2024 Results

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing…

8 months ago
Ardent Health Reports Second Quarter 2024 ResultsArdent Health Reports Second Quarter 2024 Results

Ardent Health Reports Second Quarter 2024 Results

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing…

8 months ago
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature RangeOragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,…

8 months ago
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core StrengthsEvotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book…

8 months ago
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program WinnersBausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners

Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners

For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August…

8 months ago
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded…

8 months ago
Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers SquibbEvotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Key scientific achievements drive the expansion of the pipeline of molecular glue degradersPerformance-based and programme-based payments of in total US$…

8 months ago